Melinta Therapeutics (Melinta Therapeutics) Retained Earnings : $-997.88 Mil (As of Sep. 2019)

View and export this data going back to 2012. Start your Free Trial

What is Melinta Therapeutics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Melinta Therapeutics's retained earnings for the quarter that ended in Sep. 2019 was $-997.88 Mil.

Melinta Therapeutics's quarterly retained earnings declined from Mar. 2019 ($-748.32 Mil) to Jun. 2019 ($-784.50 Mil) and declined from Jun. 2019 ($-784.50 Mil) to Sep. 2019 ($-997.88 Mil).

Melinta Therapeutics's annual retained earnings declined from Dec. 2016 ($-513.74 Mil) to Dec. 2017 ($-572.66 Mil) and declined from Dec. 2017 ($-572.66 Mil) to Dec. 2018 ($-719.84 Mil).

Melinta Therapeutics Retained Earnings Historical Data

The historical data trend for Melinta Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melinta Therapeutics Retained Earnings Chart

Melinta Therapeutics Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Retained Earnings

Get a 7-Day Free Trial

-227.91

-319.02

-513.74

-572.66

-719.84

Melinta Therapeutics Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Retained Earnings	Get a 7-Day Free Trial															-675.72	-719.84	-748.32	-784.50	-997.88

Melinta Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Melinta Therapeutics (OTCPK:MLNTQ) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Melinta Therapeutics (Melinta Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Melinta Therapeutics Inc (OTCPK:MLNTQ) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

44 Whippany Road, Morristown, NJ, USA, 07963

Website

http://www.melinta.com

Melinta Therapeutics Inc is a clinical-stage biotechnology company that develops differentiated antibiotics for acute care and community settings. The company's goal is to develop treatments for bacterial infectious diseases, particularly respiratory tract infections and staphylococcal infections. The company is particularly focused on treating community-acquired bacterial pneumonia, as well as gonorrhea and other indications.

Executives

John Johnson	director, officer: Chief Executive Officer	DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Thomas P Koestler	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
David Zaccardelli	director	300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069
David N Gill	director	C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Bruce Downey	director
Garheng Kong	director	712 COLLEGE AVENUE, MENLO PARK CA 94025
Daniel Mark Wechsler	director, officer: See Remarks	2150 ST. ELZEAR BLVD. WEST, LAVAL A8 H7L 4A8
John Temperato	officer: Chief Commercial Officer	C/O MELINTA THERAPEUTICS,INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511
Goldstein Dov A Md	director
Michael R Dougherty	director	C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
P Sherrill Neff	director	C/O RESOURCE AMERICA, INC., 1845 WALNUT STREET, 18TH FLOOR, PHILADELPHIA PA 19103
Prabhavathi Fernandes	director, officer: President and CEO	114 MILTON AVENUE, CHAPEL HILL NC 27514
Intersouth Partners Vii L P	10 percent owner	406 BLACKWELL SUITE 200, DURHAM NC 27701
Intersouth Associates Vii, Llc	10 percent owner	406 BLACKWELL STREET, SUITE 200, DURHAM NC 27701
Intersouth Associates Vi, Llc	10 percent owner	406 BLACKWELL STREET, SUITE 200, DURHAM NC 27701